Prosecution Insights
Last updated: November 04, 2026
Application No. 18/833,812

MICROFLUIDIC DEVICE COMPRISING MEMBERS FOR RETAINING OBJECTS WITHIN CAPILLARY TRAPS

Non-Final OA §102§112
Filed
Jul 26, 2024
Priority
Feb 07, 2022 — FR 2201027 +1 more
Examiner
HUANG, MICKEY NMN
Art Unit
1758
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Synchrotron Soleil
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
1y 0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
63 granted / 106 resolved
-5.6% vs TC avg
Strong +49% interview lift
Without
With
+48.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
44 currently pending
Career history
156
Total Applications
across all art units

Statute-Specific Performance

§101
6.8%
-33.2% vs TC avg
§103
40.0%
+0.0% vs TC avg
§102
23.3%
-16.7% vs TC avg
§112
26.0%
-14.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 106 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Interpretation The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 7 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Regarding claim 7, the claim recites “means for connecting/disconnecting said injection member”. However, the specification fails to provide a corresponding structure for the means for connecting/disconnecting the injection member. As such, it is determined the subject matter was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim(s) 7-8 is/are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 7, the phrase "such as" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Regarding claim 7, additionally, claim limitation “means for connecting/disconnecting said injection member” invokes 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. However, the written description fails to disclose the corresponding structure, material, or acts for performing the entire claimed function and to clearly link the structure, material, or acts to the function. The disclosure is devoid of any structure or example of connecting/disconnecting means. Therefore, the claim is indefinite and is rejected under 35 U.S.C. 112(b) or pre-AIA 35 U.S.C. 112, second paragraph. Applicant may: (a) Amend the claim so that the claim limitation will no longer be interpreted as a limitation under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph; (b) Amend the written description of the specification such that it expressly recites what structure, material, or acts perform the entire claimed function, without introducing any new matter (35 U.S.C. 132(a)); or (c) Amend the written description of the specification such that it clearly links the structure, material, or acts disclosed therein to the function recited in the claim, without introducing any new matter (35 U.S.C. 132(a)). If applicant is of the opinion that the written description of the specification already implicitly or inherently discloses the corresponding structure, material, or acts and clearly links them to the function so that one of ordinary skill in the art would recognize what structure, material, or acts perform the claimed function, applicant should clarify the record by either: (a) Amending the written description of the specification such that it expressly recites the corresponding structure, material, or acts for performing the claimed function and clearly links or associates the structure, material, or acts to the claimed function, without introducing any new matter (35 U.S.C. 132(a)); or (b) Stating on the record what the corresponding structure, material, or acts, which are implicitly or inherently set forth in the written description of the specification, perform the claimed function. For more information, see 37 CFR 1.75(d) and MPEP §§ 608.01(o) and 2181. Regarding claim 8, The addition of the word “type” to an otherwise definite expression (e.g., lab-on-a-chip) extends the scope of the expression so as to render it indefinite. Ex parte Copenhaver, 109 USPQ 118 (Bd. Pat. App. & Inter. 1955). See MPEP § 2173.02(III)(E). Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-3 and 8 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Jones (US 2015/196909 A1) as cited in IDS. Regarding claim 1, Jones discloses (para. [0046]-[0052]): a microfluidic device (100, Fig. 1) comprising: - a support comprising a microchannel (118 and 119, Fig. 2) configured to allow a fluid to flow from an inlet of the microchannel (118) to an outlet of the microchannel (119), - capillary traps (para. [0045]-[0046], Fig. 1, 2A and 5, see the microchannels formed between the columns of micropillars (105 and 106, Fig. 1) arranged in series between the inlet (118) and the outlet (119) of the microchannel, each of the capillary traps comprising a microcavity (cavity formed by sharp corner 110, Fig. 2B) formed in a wall of the microchannel (Fig. 1, 2A-C and 5) so as to open into the microchannel in order to trap one or more objects suspended in the fluid as the latter flows through the microchannel; and each of the capillary traps comprises a retaining member (103 or 104) extending in the microchannel opposite the microcavity of this capillary trap (Fig. 1, 2A-C and 5). Regarding claim 2, Jones discloses the claimed invention as discussed above in claim 1. Jones discloses the retaining member comprises a concave retaining surface (Fig. 2C; para. [0051]-[0052]). Regarding claim 3, Jones discloses the claimed invention as discussed above in claim 2. Jones discloses wherein, for each of the capillary traps, the retaining member comprises a first edge delimiting an upstream end of the retaining surface and a second edge delimiting a downstream end of the retaining surface, the first edge being located at a first distance from the microcavity of said capillary trap, the second edge being located at a second distance from the microcavity of said capillary trap, the first distance being greater the second distance (See annotated Fig. 2C below) PNG media_image1.png 333 507 media_image1.png Greyscale Regarding claim 8, Jones discloses the claimed invention as discussed above in claim 1. Jones discloses the support is a chip of a lab-on-a-chip type system (para. [0009]-[0010]). Claim(s) 1-2 and 4-10 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Solomon (US 2016/214108 A1) as cited in IDS. Regarding claim 1, Solomon discloses a microfluidic device (100, Fig. 1) comprising: - a support comprising a microchannel (112, 115, 116, Fig. 1A-C) configured to allow a fluid to flow from an inlet of the microchannel (106, Fig. 1A-C) to an outlet of the microchannel (118, Fig. 1A-C; para. [0024]), - capillary traps (Fig. 1A-C, combination of trap 102, bypass channel 104, and capillary restriction channel 114) arranged in series between the inlet (106) and the outlet (118) of the microchannel (112, 115, 116), each of the capillary traps comprising a microcavity (fluidic trap 102) formed in a wall of the microchannel so as to open into the microchannel in order to trap one or more objects suspended in the fluid as the latter flows through the microchannel (Embodiments also enable uniform trapping of cells and other particles suspended in a fluid over the entire network of traps. This is particularly important in cell-based screening studies. para. [0023]); and each of the capillary traps comprises a retaining member (114, Fig. 1A-C) extending in the microchannel (116) opposite the microcavity (102) of said capillary trap. Regarding claim 2, Solomon discloses the claimed invention as discussed above in claim 1. Solomon discloses an embodiment where the retaining member comprises a concave retaining surface (concave shape of 114, Fig. 1C). PNG media_image2.png 369 539 media_image2.png Greyscale Regarding claim 4, Solomon discloses the claimed invention as discussed above in claim 1. Solomon discloses wherein, for each of the capillary traps, the retaining member extends along a flow direction of the microchannel, having a width less than or equal to a width of the microcavity of said capillary trap (…and hydrophilic capillary constriction channels 114 with, e.g., 40 μm width (small constriction inlet) connecting main channel 110 directly to traps 102. In embodiments, square fluidic traps 102 have, e.g., 1 mm×1 mm sides…para. [0025]). Regarding claim 5, Solomon discloses the claimed invention as discussed above in claim 1. Solomon discloses microchannel is a primary microchannel, each of the capillary traps comprising a secondary microchannel opening into the microcavity of said capillary trap (bypass channel 104, Fig. 1). Regarding claim 6, Solomon discloses the claimed invention as discussed above in claim 1. Solomon discloses wherein, for each of the capillary traps, the secondary microchannel comprises: a first end through which it opens into the microcavity of said capillary trap, which opens into a second of the primary microchannel, and a second end through which it opens into another section of the primary microchannel (See annotated Figure 1 below). PNG media_image3.png 177 375 media_image3.png Greyscale Regarding claim 7, Solomon discloses the claimed invention as discussed above in claim 1. Solomon discloses the device comprising an injection member (pipettor 330, Fig. 3; para. [0033]) and means for connecting/disconnecting said injection member (interface for pipettor 330, para. [0033]). Regarding claim 8, Solomon discloses the claimed invention as discussed above in claim 1. Solomon discloses the support is a chip of a lab-on-a-chip system (para. [0056]). Regarding claim 9, Solomon discloses the claimed invention as discussed above in claim 1. Solomon discloses a method for analyzing objects comprising a step of injecting a fluid into the microchannel of a microfluidic device according to claim 1 (This injection of fluid into the channels is achieved at high flow rates using a commercially available pipetting system. Para. [0044]), said objects being suspended in the fluid thus injected (A cell suspension may be loaded using either a manual or electronic pipette into a gridded microfluidic trap. para. [0054]). Regarding claim 10, Solomon discloses the method as discussed above in claim 9. Solomon discloses the method comprises a step of optically detecting objects retained by the capillary traps of the microfluidic device (The cells within the traps were counted and used to calculate the total population. Para. [0054]). Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Lyubimov (Capture and X-ray diffraction studies of protein microcrystals in a microfluidic trap array, 2015) cited in the IDS discloses microfluidic device (Fig. 3) comprising traps and bypass channels (Fig. 3B-3C) wherein the traps is a concave shape (Fig. 2C). Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICKEY HUANG whose telephone number is (571)272-7690. The examiner can normally be reached M-F 9:30-5:30 PM ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maris Kessel can be reached at 5712707698. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /M.H./Examiner, Art Unit 1758 /MARIS R KESSEL/Supervisory Patent Examiner, Art Unit 1758
Read full office action

Prosecution Timeline

Jul 26, 2024
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773692
Self-Contained Nucleic Acid Processing
5y 3m to grant Granted Oct 27, 2026
Patent 12761225
Device for collecting, preserving and storing eukaryotic cells contained in a sample of biological fluid for further cell analysis
5y 2m to grant Granted Oct 13, 2026
Patent 12687530
METHOD FOR DETERMINING THE ACIDITY OF AN ACIDIC AQUEOUS SOLUTION
4y 1m to grant Granted Jul 21, 2026
Patent 12687518
ANALYSIS METHOD AND ANALYSIS DEVICE
4y 2m to grant Granted Jul 21, 2026
Patent 12674797
METHOD FOR MEASURING NUCLEIC ACID CONTENT IN LIPID NANOPARTICLES USING ULTRAVIOLET SPECTROMETRY
4y 3m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+48.7%)
3y 4m (~1y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 106 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month